Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases (2023 - 2025)

Contineum Therapeutics has reported Operating Leases over the past 3 years, most recently at $4.0 million for Q3 2025.

  • Quarterly results put Operating Leases at $4.0 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $4.0 million (changed N/A YoY), and the annual figure for FY2024 was $6.3 million, up 5695.37%.
  • Operating Leases for Q3 2025 was $4.0 million at Contineum Therapeutics, down from $4.3 million in the prior quarter.
  • Over the last five years, Operating Leases for CTNM hit a ceiling of $6.3 million in Q4 2024 and a floor of $108000.0 in Q4 2023.
  • Median Operating Leases over the past 3 years was $4.0 million (2025), compared with a mean of $2.8 million.
  • Biggest five-year swings in Operating Leases: surged 5695.37% in 2024 and later soared 3691.15% in 2025.
  • Contineum Therapeutics' Operating Leases stood at $108000.0 in 2023, then surged by 5695.37% to $6.3 million in 2024, then crashed by 35.84% to $4.0 million in 2025.
  • The last three reported values for Operating Leases were $4.0 million (Q3 2025), $4.3 million (Q2 2025), and $4.5 million (Q1 2025) per Business Quant data.